IGF-1R
シグナル伝達経路
研究分野
- 阻害剤の選択性比較
- 溶解度
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S1091 | Linsitinib (OSI-906) | <1 mg/mL | 84 mg/mL | <1 mg/mL |
| S1034 | NVP-AEW541 | <1 mg/mL | 88 mg/mL | <1 mg/mL |
| S1093 | GSK1904529A | <1 mg/mL | 124 mg/mL | <1 mg/mL |
| S1088 | NVP-ADW742 | <1 mg/mL | 10 mg/mL | 3 mg/mL |
| S1012 | BMS-536924 | <1 mg/mL | 96 mg/mL | <1 mg/mL |
| S2703 | GSK1838705A | <1 mg/mL | 107 mg/mL | <1 mg/mL |
| S1124 | BMS-754807 | <1 mg/mL | 92 mg/mL | 92 mg/mL |
| S8003 | PQ 401 | <1 mg/mL | 32 mg/mL | <1 mg/mL |
| S7106 | AZD3463 | <1 mg/mL | 24 mg/mL | <1 mg/mL |
| S8228 | NT157 | <1 mg/mL | 82 mg/mL | 82 mg/mL |
| S7668 | Picropodophyllin (PPP) | <1 mg/mL | 82 mg/mL | 1 mg/mL |
亜型選択性的な製品
- IGF-1R阻害剤(11)
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S1091 |
Linsitinib (OSI-906)Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3. |
(e) c-peptide from these mice 240 min after respective treatments.
|
|
| S1034 |
NVP-AEW541NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay. |
(A) KRAS mutant (SW837 and LoVo) or KRAS/PIK3CA mutant (HCT-116) colorectal cancers were treated with the indicated compounds for 6 hours (gef, gefitinib 1 μM; NVP, NVP-AEW541 1 μM; PHA, PHA-665752 1 μM), and the resulting protein lysates were immunoprecipitated with an anti-p85 antibody. The precipitated proteins were analyzed by Western blots with the indicated antibodies. Whole cell extracts were probed with the indicated antibodies. Asterisks indicate the IRS proteins for SW837 and HCT-116 cells, and ERBB3 for LoVo cells. (B) SW837 cells were grown in either normal serum (5% FBS) or low serum (0.5% FBS) and treated with vehicle, R1507 anti–IGF-IR antibody (25 μg/ml), or NVP-AEW541 (1 μM) for 6 hours. The cells were lysed and probed with the indicated antibodies. |
|
| S1093 |
GSK1904529AGSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc. |
(E) The level of migration ability of HEC-1B cells treated with insulin, GSK1904529A, and the silencing of DHCR24 was determined using a transwell assay. (F) The invasion ability of HEC-1B cells treated with insulin, GSK1904529A, and silencing of DHCR24 was probed. The data are presented as the mean ± SD of three independent experiments. (*p < 0.05; **p < 0.01; ***p < 0.001).
|
|
| S1088 |
NVP-ADW742NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit. |
Relative cell viability of 72 hours of treatment with IGF1R/IR inhibitors. a-b OSI-906 does not inhibit chondrosarcoma cell viability, even in the presence of IGF1. c-d IGF1R inhibitors NVP-ADW742 and GSK1838705A do not inhibit chondrosarcoma cell viability
|
|
| S1012 |
BMS-536924BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2. |
|
|
| S2703 |
GSK1838705AGSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases. |
Protective effect of IGF1 on Sorafenib or VK1-mediated actin cytoskeleton redistribution in HCC cells. PLC/PRF/5 and HLF cells were stained with DyLight 554 Phalloidin after treatment with 1 μM Sorafenib, 12 μM VK1 or 1 μM GSK1838705A (GSK) for 24 h alone or in combination with 40 ng/ml IGF1. Scale bar: 100 μm.
|
|
| S1124 |
BMS-754807BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2. |
|
|
| S8003 |
PQ 401PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM. |
PQ401 induces apoptosis in glioma cells. (A) U87MG cells were treated with PQ401 at the indicated concentrations for 48 hours, followed by PI staining and flow cytometry analysis. * indicates P < 0.05 by one-way ANOVA followed by Dunnet's test for comparisons between PQ401 treatments with various doses and no PQ401 treatment group. (B) U87MG cells were incubated with PQ401 for 48 hours. The nuclei were stained with Hoechst and analyzed using a fluorescent microscope. The representative images are presented. (C) The number of cells with condensed/fragmented nuclei was quantitated by counting in seven random fields and the inhibition was calculated. * indicates P < 0.05 by one-way ANOVA followed by Dunnet's test for comparisons between PQ401 treatments with various doses and no PQ401 treatment group.
|
|
| S7106 |
AZD3463AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency. |
(E) Immunoblot analysis of lysates of A4573 and TC32 cells following exposure to media only (Control, C); ST/V and V/ST with (+) or without (-) 20 nM AZD3463 using antibodies against ALK, IGF-1R, STAT3 (Y705), p-STAT3, AKT, p-AKT (S473), MAPK, p-MAPK (p42/44). |
|
| S8228 |
NT157NT157, a selective inhibitor of IRS-1/2(insulin receptor substrate), has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival. |
||
| S7668 |
Picropodophyllin (PPP)Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). |
(E): Expression levels of NANOG and p-IGF-IR were measured by immunoblotting in HCT116 and SW620 cells after treatment with IGF-II or PPP.
|
-Clin-Cancer-Res-20150727.gif)
